Some individuals who struggle with weight reduction have been capable of find help with several FDA-approved weight reduction medications, corresponding to bupropion plus naltrexone (Contrave), phentermine (Adipex-P), phentermine plus topiramate (Qsymia) and orlistat (Xenical, Alli). On average, such drugs will help people lose 5% to 7% of their body weight when paired with a healthy eating regimen and exercise.
Now a brand new class of medication used to treat type 2 diabetes has gained attention for its impressive weight reduction results — in lots of cases, 10% to twenty% of an individual's body weight. They are called glucagon-like peptide-1 (GLP-1) receptor agonists.
A tale of two drugs
Two of those GLP-1 receptor agonists are FDA-approved formulations designed specifically for weight reduction in people without diabetes: liraglutide (Sexanda) and semaglutide (Vigovi).
Low-dose versions of the identical lively ingredients, often known as Victoza and Ozempic, respectively, have been used for years to assist individuals with diabetes control their blood sugar levels.
New drugs on the horizonOther GLP-1 receptor agonists for weight reduction may soon change into available. A recent trial funded by Eli Lilly, which makes tericeptide (Monjaro), found that about half of the participants with each obesity and kind 2 diabetes lost about 15 percent of their body weight on the drug. In addition, early research suggests that retatrotide, a triple hormone receptor agonist (acts on receptors for GLP-1, GIP, and CGCR), may cause as much as 25 percent weight reduction in individuals with diabetes. The FDA approved terceptide for the treatment of type 2 diabetes in May 2022 and is now evaluating whether to approve it for the treatment of obesity. 
|
How do latest drugs work?
GLP-1 receptor agonists mimic the GLP-1 hormone that is of course released within the stomach in response to food.
“The drugs stimulate the body to produce more insulin after meals, limiting postprandial blood sugar levels, which is especially important for people with type 2 diabetes,” says Dr. Caballero. Medicines also control appetite by sending signals to the brain to inform the body that it's full, which prevents overeating.
It is very important to do not forget that these drugs are only approved for individuals who meet certain criteria. Vigovi and Saxenda are for adults diagnosed with obesity — a body mass index (BMI) of 30 or more — or with a BMI of 27 plus at the least one weight-related condition, corresponding to hypertension, high cholesterol, or type 2 diabetes. Other versions of those drugs – Victoza and Ozempic – are for individuals with type 2 diabetes.
Still, that hasn't stopped some doctors from prescribing these weight-loss drugs “off-label,” meaning they're used for purposes aside from those clearly intended. “But there's not enough evidence to know whether these drugs may be beneficial or dangerous for people outside the FDA's criteria,” says Dr. Caballero.
However, the larger problem is that many individuals see latest drugs as a fast fix. “It's important to remember that all weight loss medications are recommended as an aid to an overall strategy that focuses on a healthy eating plan and regular physical activity,” says Dr. Caballero. “In fact, people who stop taking these medications often regain weight unless they have made truly permanent and effective changes in their eating and physical activity habits.”
Know the downsides.
When discussing along with your doctor whether GLP-1 receptor agonists are price exploring, it is important to know their potential downsides. You may experience various gastrointestinal unintended effects, including gas, bloating, indigestion, nausea, or bowel irregularities.
But these problems often resolve inside a number of weeks, in accordance with Dr. Caballero. “The lowest doses of these drugs are usually given first and then gradually increased so people are less likely to have side effects,” he says.
Another downside is the associated fee. Medicines are expensive – about $1,000 to $1,500 monthly. Even if you happen to qualify for his or her use, the drugs should not covered by Medicare for obesity, although Victoza and Ozempic are covered by Medicare and most private insurers for the treatment of type 2 diabetes. Finally, bear in mind that drugs are given by injection into the arm, abdomen, or thigh using a pen-like device with a small needle the width of two human hairs. (Semaglutide is given weekly, while liraglutide injections are given each day.) Semaglutide, prescribed for diabetes, is now also available as a each day pill called Rybilus. You must wait half-hour to an hour after taking it before eating or drinking.
Photo: © 3dfoto/Getty Images